Invesco Ltd. Has $501,000 Holdings in Harrow, Inc. (NASDAQ:HROW)

Invesco Ltd. trimmed its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 92.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,919 shares of the company's stock after selling 184,105 shares during the period. Invesco Ltd.'s holdings in Harrow were worth $501,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after purchasing an additional 194,480 shares during the period. Barclays PLC lifted its position in Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after buying an additional 39,506 shares during the last quarter. Brookstone Capital Management purchased a new position in shares of Harrow during the 4th quarter worth approximately $275,000. SG Americas Securities LLC grew its stake in shares of Harrow by 158.5% in the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after buying an additional 18,815 shares in the last quarter. Finally, Sonora Investment Management Group LLC acquired a new stake in shares of Harrow during the fourth quarter worth about $518,000. 72.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price target on shares of Harrow in a research report on Monday, March 31st. B. Riley decreased their price target on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st.

Harrow Stock Performance

Shares of HROW traded up $0.95 during mid-day trading on Friday, hitting $24.54. 881,703 shares of the company's stock were exchanged, compared to its average volume of 509,884. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a fifty-two week low of $10.08 and a fifty-two week high of $59.23. The business's 50 day moving average is $24.83 and its two-hundred day moving average is $33.04. The firm has a market capitalization of $900.25 million, a P/E ratio of -26.11 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. On average, equities analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.